Aqilion focuses on diseases caused by chronic inflammation and dysfunctional immunological reactions
We explore novel scientific findings describing the biology behind the diseases and focus on developing new innovative treatments. Our mission is clear, we identify opportunities based on solid research resting on a firm biological foundation offering both clinical relevance and patient benefit.
What we do
Research is at the heart of what we do. The Aqilion team and network has extensive expertise and experience in pursuing research to develop innovative medicines that can make a difference in the treatment of diseases in which the body’s inflammatory processes play a major role.
Pipeline
Aqilion runs four innovative R&D programs. All with focus on developing novel innovative treatments for chronic inflammatory diseases for which few or no treatments are available and where there is currently a clear patient need.
Press releases
Aqilion to Present Preclinical Data at Digestive Disease Week, May 2–5, Demonstrating That AQ280 Counteracts Dysfunctional Epithelial Barrier Function in Eosinophilic Esophagitis
Aqilion sharpens focus on AQ280 and AQ128 – ready for the next phase in inflammatory diseases
Positive Results from Clinical Pharmacokinetic Study for the Eosinophilic Esophagitis Specific Formulation with the Drug Candidate AQ280
Subscribe
Interim Reports are distributed to shareholders only.